Loading…
← CockpitCompetitor Analysis › 688336.SS Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class AOpen in the cockpit ↗

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A688336.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Biologics arm of 3SBio making monoclonal antibodies and biosimilars for autoimmune disease and oncology.

≈ A China biosimilar unit akin to a small Amgen biosimilars armMomentum laggard 8
Mkt cap
$3.81B
US dollars, full cap
Free float
15%
of shares outstanding
$/day
$25.3M
20-day average traded
Fwd P/E
39.9×
forward earnings
ROIC−WACC
+23.7 pp
WACC 9.5%
Hurdle
-44 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥28.25
1D-2.6%
1W-13.8%
1M-19.5%
3M-40.6%
6M-38.5%
YTD-31.2%
1Y-46.5%
ATR %6.3%
52w lowhigh57.6% off high

What Sunshine Guojian Pharmaceutical (Shanghai) does

Biologics arm of 3SBio making monoclonal antibodies and biosimilars for autoimmune disease and oncology.

In one line: A China biosimilar unit akin to a small Amgen biosimilars arm.

Products and services

  • Biosimilar antibodies (e.g. adalimumab)
  • Innovative biologics pipeline

Customers

  • Hospitals

Where it sits in the supply chain

  • Biotechnology
  • Monoclonal antibody manufacturing
  • Biosimilars & innovative biologics

What could go right

  • Biosimilar approvals and hospital listing
  • Parent 3SBio commercial support

What could go wrong

  • Biosimilar price competition
  • VBP drug pricing pressure

Moat: narrow (process know-how, IP / patents). In-house antibody manufacturing and an affiliate relationship with parent 3SBio's commercial network.

Headquarters: Shenyang, China · Founded: 2002 · Employees: 1,012

Named competitors

Sunshine Guojian Pharmaceutical (Shanghai) at a glance

Size Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.81B, the 632nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.25 on 18 Nov 2026.

Performance Over six months the shares fell 38.5%, against +3.5% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue grew 227.2% over the last twelve months (peer median +8.4%); the operating margin is 73.8% (peer median 15.7%).

Valuation It trades at 39.9× forward earnings against a peer median of 18.5× (4th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -44 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 23.7 points above its cost of capital (9.5% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 104688336.SS 63
Six months, rebased to 100: Sunshine Guojian Pharmaceutical (Shanghai) against the median of its 20 peers (local-currency closes).

Sunshine Guojian Pharmaceutical (Shanghai) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.48BCN¥4.20BCN¥1.19BCN¥1.01BCN¥823M
Revenue growth—+253%+18%+23%—
Gross profitCN¥4.19BCN¥3.82BCN¥836MCN¥743MCN¥564M
EBITDAn/aCN¥3.24BCN¥335MCN¥287MCN¥85.0M
Net incomeCN¥3.09BCN¥2.90BCN¥705MCN¥295MCN¥49.3M
Free cash flowCN¥181MCN¥2.94BCN¥484MCN¥203MCN¥42.3M
Capital expenditureCN¥276MCN¥253MCN¥281MCN¥236MCN¥221M
Total debtCN¥0CN¥0CN¥50.0MCN¥50.0MCN¥150M

Quarterly statements and history in the cockpit →

Sunshine Guojian Pharmaceutical (Shanghai) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%000513600329ROVITARSXENE128940SLSDFTX6005213320000100WOCKPHARMA4536ACUTAAS1877ARQT688336.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sunshine Guojian Pharmaceutical (Shanghai) is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×60×000513600329ROVI128940OGN3320000100SFZNACUTAASARQT688336.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sunshine Guojian Pharmaceutical (Shanghai) is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%000513600329ROVITARS301569ARQT688336.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sunshine Guojian Pharmaceutical (Shanghai) is the large dot.

Sunshine Guojian Pharmaceutical (Shanghai) competitors and peer comparison

Head to head with its named competitors (688336.SS vs 1530.HK vs 1801.HK vs 688177.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS$3.81B-38%+227%74%39.9×0.9%
3SBio 1530.HK$4.28B-31%+102%61%12.0×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Bio-Thera Solutions 688177.SS$929M-23%+24%-44%n/an/a
Shanghai Henlius Biotech 2696.HK$3.05B-39%+33%12%21.3×14.1%

How Sunshine Guojian Pharmaceutical (Shanghai) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sunshine Guojian Pharmaceutical (Shanghai) against its 20 peers (data as of 18 Nov 2026)
Measure688336.SSPeer medianRank in peer set
1-month return-19.5%+2.6%2nd lowest of 21
6-month return-38.5%+3.5%lowest of 19
Distance from 52-week high-57.6%-26.4%2nd lowest of 21
Revenue growth (TTM)+227.2%+8.4%highest of 18
Operating margin73.8%15.7%highest of 17
Forward P/E39.9×18.5×4th most expensive of 13
Growth the price implies (Req g, 7 yrs)0.9%5.5%5th least demanding of 13
Growth delivered (Del g)+45.1%+5.0%3rd highest of 13
Hurdle (Req g minus delivered)-44.2 pp-5.6 pp3rd least demanding of 13
ROIC minus cost of capital+23.7 pp+4.3 pphighest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%

Questions

Who are Sunshine Guojian Pharmaceutical (Shanghai)'s main competitors?
Named competitors: 3SBio (1530.HK), Innovent Biologics (1801.HK), Bio-Thera Solutions (688177.SS), Henlius Biotech (2696.HK). The cockpit's measured peer set (industry) also includes Livzon Pharmaceutical (000513.SZ), Tianjin Pharmaceutical Da Ren Tang (600329.SS), Laboratorios Farmaceuticos Rovi (ROVI.MC), Tarsus Pharmaceuticals (TARS), Xenon Pharmaceuticals (XENE), Novast Laboratories (301569.SZ).
Is Sunshine Guojian Pharmaceutical (Shanghai) expensive compared with its peers?
On forward p/e it trades at 39.9× against a peer median of 18.5×, 4th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -44 pp: the price already allows for a slowdown.
How has Sunshine Guojian Pharmaceutical (Shanghai) stock performed?
Over six months to 18 Nov 2026 the shares returned -38.5% against +3.5% for the median peer; over one year -46.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.